FullCircle Wealth’s Thermo Fisher Scientific TMO Stock Holding History

FullCircle Wealth’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-702	Closed	-$296K	–	275
2025 Q1	$296K	Buy	702 +17	+2%	+$9.21K	0.12%	167
2024 Q4	$365K	Sell	685 -3	-0.4%	-$1.65K	0.15%	144
2024 Q3	$380K	Buy	688 +6	+0.9%	+$3.55K	0.17%	137
2024 Q2	$392K	Buy	+682	New	+$391K	0.19%	126

Other funds holding TMO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

FullCircle Wealth's TMO Position: Q2 2025 in Review

FullCircle Wealth sold out of Thermo Fisher Scientific (TMO) in Q2 2025, closing a stake of 702 shares — an estimated $296K sold.

FullCircle Wealth first reported a position in TMO in Q2 2024 and held it in 4 quarters. The position peaked at $392K in Q2 2024. 2,453 funds tracked by Wall St. Rank hold TMO as of Q2 2025.

FullCircle Wealth reported no remaining Thermo Fisher Scientific position as of Q2 2025 after selling out during the quarter.
FullCircle Wealth sold 702 Thermo Fisher Scientific shares in Q2 2025, an estimated $296K.
FullCircle Wealth first reported a position in Thermo Fisher Scientific in Q2 2024 and held it in 4 quarters.
FullCircle Wealth's Thermo Fisher Scientific position peaked at $392K in Q2 2024.
2,453 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2025.

Based on FullCircle Wealth's 13F filing for Q2 2025, filed 5 Aug 2025.